We also found that the higher expression levels of the twenty-nine ET-125 genes that contain ZNF92 binding sites correlate with overall and relapse-free survival in HER2+, Luminal-B, TNBC, and basal-like breast cancers independent of grade and treatment (Fig. 6f–h, Supplementary Fig. 12). This evidence concerns the gene ZNF92 and breast carcinoma.